title: Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.
abstract: Newcastle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alone or with monomeric BaL gp120 and BaL SOSIP gp140 protein in a prime-boost combination in guinea pigs to enhance envelope (Env)-specific humoral and mucosal immune responses. We showed that a regimen consisting of an NDV prime followed by a protein boost elicited stronger serum and mucosal Th-1-biased IgG responses and neutralizing antibody responses than NDV-only immunizations. Additionally, these responses were higher after the gp120 than after the SOSIP gp140 protein boost.
authors.affiliation: Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Khattar
authors.affiliation: Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Anthony L
authors.initials: AL
authors.lastname: DeVico
authors.affiliation: Division of Surgical Sciences, Duke University, Durham, North Carolina, USA.
authors.forename: Celia C
authors.initials: CC
authors.lastname: LaBranche
authors.affiliation: Program of Comparative Medicine, Departments of Pathology, Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Aruna
authors.initials: A
authors.lastname: Panda
authors.affiliation: Division of Surgical Sciences, Duke University, Durham, North Carolina, USA.
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.affiliation: Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA ssamal@umd.edu.
authors.forename: Siba K
authors.initials: SK
authors.lastname: Samal
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000276:immunology*; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D007273:Injections, Intramuscular; D009500:Neutralization Tests; D009522:Newcastle disease virus / Q000235:genetics; D018417:Th1 Cells / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D004337:Drug Carriers; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D054299:env Gene Products, Human Immunodeficiency Virus; C514793:gp120 protein, Human immunodeficiency virus 1; C097729:gp140 envelope protein, Human immunodeficiency virus 1; C514797:gp160 protein, Human immunodeficiency virus 1